39 results about "Chlamydophila Pneumonia" patented technology

The invention discloses a kit for quickly detecting 15 pneumonia pathogenic bacteria. The kit can detect streptococcus pneumoniae, staphylococcus aureus, haemophilus influenzae, mycoplasma pneumoniae, pseudomonas aeruginosa, baumanii, enterococcus faecalis, enterococcus faecium, klebsiella pneumoniae, escherichia coli, enterobacter cloacae, stenotrophomonas maltophilia, burkholderia cepacia, legionella pneumophila and chlamydia pneumoniae which cover clinically common pneumonia pathogenic bacteria difficult to culture. 16S rDNA and specific gene sequences corresponding to the pneumonia pathogenic bacteria are detected by combining gene chips with multiple asymmetric PCR reactions, and the categories of the bacteria in a to-be-detected sample are identified in genus and species. The kit makes up for the defect that current clinical detection of pneumonia pathogenic bacteria is not in time or comprehensive and a novel detection means for early diagnosis and early treatment of patients suffering from pneumonia is provided.

The invention relates to the technical field of biology, in particular to a primer probe combination and a detection kit for detecting mycoplasma pneumoniae, chlamydia pneumoniae and adenovirus. The primer probe combination comprises a specific primer pair of mycoplasma pneumoniae shown in SEQ ID NO: 1-2, a specific probe of mycoplasma pneumoniae shown in SEQ ID NO:3, a specific primer pair of chlamydia pneumoniae shown in SEQ ID NO: 4-5, a specific probe of chlamydia pneumoniae shown in SEQ ID NO:6, a specific primer pair of adenovirus shown in SEQ ID NO: 7-8 and a specific probe of adenovirus shown in SEQ ID NO: 9. The primers and the probes have good specificity, and rapid, accurate and sensitive identification of MP, CP and ADV can be achieved in combination with a real time PCR detection method.

The invention discloses a chlamydia pneumoniae IgM (immunoglobulin M) colloidal golden method kit which comprises recombinant chlamydia pneumoniae antigens enveloped on a nitrocellulose membrane detection line, goat anti-rat IgG (immunoglobulin G) antibodies enveloped on a quality control line and rat anti-human IgM monoclonal antibodies which have colloidal gold labels and are enveloped on a gold label pad, the concentration of the chlamydia pneumoniae antigens ranges from 1mg/ml to 2mg/ml and is measured by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis), the concentration of the goat anti-rat IgG (immunoglobulin G) antibodies ranges from 1mg/ml to 3mg/ml, and the concentration of the rat anti-human IgM monoclonal antibodies ranges from 5g/mL to 30g/mL and is measured by the SDS-PAGE. The chlamydia pneumoniae IgM colloidal golden method kit has the advantages that the kid is speedy, simple, convenient and accurate and is high in sensitivity, and a judgment result can be read after integral operation time of dozens of minutes; and a colloidal gold quick detecting paper strip is made of the multi-epitope recombinant antigens and is simple and convenient to operate, low in cost, good in specificity and high in sensitivity, can be used for single-component detection and is popularized easily, and detection and control effects for chlamydia pneumoniae IgM are obvious.

The present invention relates to oligonucleotides useful for determining the presence of Chlamydophila pneumoniae in a test sample. The oligonucleotides of the present invention may be incorporated into detection probes, capture probes and amplification oligonucleotides, and used in various combinations thereof.

The invention discloses an application of heterocyclic compounds in preparation of medicines for treating pneumonia, and relates to the technical field of biomedicine. According to the application ofthe heterocyclic compounds in the preparation of the medicines for treating the pneumonia provided by the invention, the heterocyclic compounds have anti-pneumonia activity, wherein the pneumonia includes but is not limited to viral pneumonia, bacterial pneumonia, mycoplasma pneumonia, and chlamydia pneumonia. The anti-pneumonia pharmacological activity of the structurally modified and transformedheterocyclic compounds is tested, the pharmacological activity of the compounds is tested in multiple pneumonia models, and data of anti-pneumonia activity are provided to confirm that the heterocyclic compounds all have excellent anti-pneumonia activity, that is, the heterocyclic compounds with antipneumonia activity are screened out, so that a novel skeleton can be provided for screening a novel compound for treating the pneumonia, and a theoretical foundation is laid for development of a novel lead compounds.

The invention discloses a preparation method and an application method of a chlamydia pneumoniae (CP) recombinant antigen, wherein the preparation method of the CP recombinant antigen comprises the following specific steps: selection of CP recombinant antigen sequences; prokaryotic expression of the CP recombinant antigen; purification and renaturation of CP recombinant antigen; and verification of CP recombinant antigen. A serological detection method is developed on the premise of preparing an effective CP antigen, a preparation process of a CP natural antigen is complicated and high in cost, and there is a risk of infection for preparation personnel. Using the recombinant antigen with strong immunogenicity and good specificity as a substitute of the natural antigen not only reduces production cost, but also lays a foundation for developing a detection kit for detecting CP antibodies, IGG and IgM. The method is simple in operation and low in cost, the CP antigen is strong in specificity and good in stability, capable of achieving mass production and suitable for popularization and application.

The invention relates to the field of biological reagents, in particular to coating liquid for improving the stability of chlamydia pneumoniae antigen/mycoplasma antigen in an immunochromatographic reagent and a preparation method thereof. The coating solution comprises a buffer solution, wherein the buffer solution comprises a first component for immobilizing a chlamydia antigen or a mycoplasma antigen on a nitrocellulose membrane, a stabilizer, an antioxidant and a preservative. The first component is beneficial to immobilization of the antigen on the nitrocellulose membrane. The stabilizercan improve the stability of the mycoplasma antigen and the chlamydia antigen. The antioxidant can prevent the mycoplasma antigen and the chlamydia antigen from being oxidized. The preservative can play a role in preventing mycoplasma antigens and chlamydia antigens from being corroded. All the components in the coating liquid cooperate with one another to protect the stability of the antigen in the immunochromatographic reagent.

The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector containing a nucleotide sequence encoding full-length, 5'-truncated or 3'-truncated 76 kDa protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the 76 kDa protein gene in the host. Modifications are possible within the scope of this invention.

The invention belongs to the field of medical detection equipment, and provides a combined device for synchronously detecting IgM antibodies of influenza A and B viruses and chlamydia pneumoniae and mycoplasma pneumoniae. The device comprises a double-channel clamping shell, a test strip FluA & B and a test strip CP & MP which are arranged in the double-channel clamping shell in parallel; influenza virus A detection lines arranged on a nitrocellulose membrane of the test strip FluA & B at intervals are coated with high-specificity influenza virus A antigens, influenza virus B detection linesare coated with high-specificity influenza virus B antigens, and first quality control lines are coated with quality control line coating receptors; chlamydia pneumoniae detection lines (CP) arranged on a nitrocellulose membrane of the test strip CP & MP at intervals are coated with high-specificity chlamydia pneumoniae antigens, mycoplasma pneumoniae detection lines (MP) are coated with high-specificity mycoplasma pneumoniae antigens, and second quality control lines are coated with quality control line coating receptors.

The invention discloses a fluorescent quantitative PCR method for detecting toxigenic chlamydia pneumoniae and a kit. The method ingeniously applies specific gene detection to distinguish chlamydia pneumoniae from other chlamydia and toxigenic and non-toxigenic chlamydia pneumoniae, and obtains accurate bacterial information through comprehensive judgment. Compared with the existing mainstream detection kit, the kit for detecting toxigenic chlamydia pneumoniae has the advantages of high sensitivity, quickness, convenience, good specificity, rigorous and accurate judgment and the like, and hasgood application prospect and market value.

In alternative embodiments, provided are pharmaceutical compositions and methods for treatment, amelioration and prevention of infection-associated blood vessel diseases, and also for the treatment, amelioration and prevention of non-vessel diseases affected by infective agents which can be treated by these compositions. In alternative embodiments, one common pathogen targeted by compositions and methods as provided herein is Chlamydia and Chlamydophila species, including pneumoniae, trachomatis and psittaci species which infect humans, including Chlamydophila penumoniae which also infects humans. In alternative embodiments, pathogens targeted and infections (diseases) treated ameliorated, or prevented by compositions and methods as provided herein include Mycoplasma, Listeria, Leptospirosis, Q fever or Coxiella burnetii infection, Lyme disease or Lyme borreliosis or any Borrelia infection, and Bartonella or of the family Bartonellaceae, including cat scratch disease.

The invention discloses a method for detecting respiratory pathogens in a to-be-detected sample and a kit and application thereof, and relates to the technical field of biology. The method comprises the step of detecting a to-be-detected sample with a first reagent for detecting influenza A virus, a second reagent for detecting influenza B virus, a third reagent for detecting mycoplasma pneumoniae and/or a fourth reagent for detecting chlamydia pneumoniae, and a new way is provided for effectively detecting respiratory pathogens or simultaneously detecting multiple respiratory pathogens.

The invention provides a chlamydia pneumoniae quantum dot immunochromatographic assay detection card and a preparing method and application thereof. The detection card comprises a bottom board, a sample pad, a water absorbing pad, a combining pad and a detection layer. Chlamydia pneumoniae resisting nanometer probes labeled with quantum dots envelop combining pad. The detection layer is formed by a solid-phase nitrocellulose membrane with a detection line and a quality control line. Anti-mouse chlamydia pneumoniae 98KD membrane protein polyclonal antibodies envelop the detection line. Anti-rabbit IgG is encapsulated in the quality control line. The detection layer is bonded to the bottom board. The combining pad and the water absorbing pad are arranged on the upper portions of the two ends of the detection layer respectively, partially overlapped with the detection layer and then bonded to the detection layer and the bottom board. The sample pad is arranged on the combining pad, partially overlapped with the combining pad and then bonded to the combining pad and the bottom board. The chlamydia pneumoniae quantum dot immunochromatographic assay detection card has the advantages of being easy and convenient to operate, fast in detection, capable of achieving quantification, high in sensitivity and the like.

The invention belongs to the technical field of detection of mycoplasma pneumoniae and chlamydia pneumoniae, and particularly relates to a primer probe group, a kit and a detection method for combineddetection of mycoplasma pneumoniae and chlamydia pneumoniae based on a fluorescence RMA method. The kit comprises a detection tube containing an amplification reaction reagent, a buffer solution, magnesium acetate, standard positive plasmids and sterile double distilled water. The amplification reaction reagent is prepared from primers and probes of MP and Cpn, M-MLV reverse transcriptase, escherichia coli RecA protein, UvsY protein, single-stranded binding protein GP32, Bst polymerase, exonuclease III, polyethylene oxide, trehalose, mannitol, ATP, dNTPs, creatine kinase and creatine phosphate. The standard positive plasmids are recombinant plasmids containing MP and Cpn amplified gene sequences, and are used for positive control of MP and Cpn nucleic acid detection.

The invention relates to polypeptides for use as an autotransporter antigen. The invention further relates to methods and uses of a polypeptide for an autotransporter function in preparation of a medicament for the prevention or treatment of a Chlamydia pneumoniae infection or for the preparation of an assay for the diagnosis of a Chlamydia pneumoniae infection in an individual. Also, a method is provided for raising an immune response in an individual by administering to the individual a polypeptide for use as an autotransporter antigen.

The invention discloses a mycoplasma pneumoniae and chlamydia pneumoniae IgM antibody and IgG antibody joint detection kit which comprises a first reagent strip and a second reagent strip, the first reagent strip is a mycoplasma pneumoniae and chlamydia pneumoniae IgM detection reagent strip, and the second reagent strip is a mycoplasma pneumoniae and chlamydia pneumoniae IgG detection reagent strip. The combination pad of the first reagent strip is coated with an IgM antibody-biotin-avidin-colloidal gold compound marked by colloidal gold, and the combination pad of the second reagent strip is coated with an IgG antibody-biotin-avidin-colloidal gold compound marked by colloidal gold. According to the joint detection kit, mutual interference between the IgG antibody and the IgM antibody is avoided, the joint detection accuracy is improved, the IgM antibody and the IgG antibody of mycoplasma pneumoniae and chlamydia pneumoniae can be detected at the same time, and the requirement of clinical detection can be well met.